- Home
- WDC vs BIIB Comparison
WDC vs BIIB Comparison
Compare WDC & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WDC
- BIIB
- Stock Information
- Founded
- WDC 1970
- BIIB 1978
- Country
- WDC United States
- BIIB United States
- Employees
- WDC N/A
- BIIB N/A
- Industry
- WDC Electronic Components
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- WDC Technology
- BIIB Health Care
- Exchange
- WDC Nasdaq
- BIIB Nasdaq
- Market Cap
- WDC 18.1B
- BIIB 18.8B
- IPO Year
- WDC N/A
- BIIB 1991
- Fundamental
- Price
- WDC $66.14
- BIIB $133.99
- Analyst Decision
- WDC Buy
- BIIB Buy
- Analyst Count
- WDC 22
- BIIB 27
- Target Price
- WDC $70.86
- BIIB $188.17
- AVG Volume (30 Days)
- WDC 6.5M
- BIIB 1.3M
- Earning Date
- WDC 07-30-2025
- BIIB 07-31-2025
- Dividend Yield
- WDC 0.61%
- BIIB N/A
- EPS Growth
- WDC N/A
- BIIB 26.39
- EPS
- WDC 4.55
- BIIB 10.12
- Revenue
- WDC $15,605,000,000.00
- BIIB $9,816,400,000.00
- Revenue This Year
- WDC N/A
- BIIB N/A
- Revenue Next Year
- WDC $8.21
- BIIB N/A
- P/E Ratio
- WDC $21.83
- BIIB $13.27
- Revenue Growth
- WDC 123.41
- BIIB 1.59
- 52 Week Low
- WDC $28.83
- BIIB $110.04
- 52 Week High
- WDC $66.83
- BIIB $238.00
- Technical
- Relative Strength Index (RSI)
- WDC 77.26
- BIIB 56.84
- Support Level
- WDC $63.67
- BIIB $129.08
- Resistance Level
- WDC $66.83
- BIIB $137.84
- Average True Range (ATR)
- WDC 1.50
- BIIB 4.01
- MACD
- WDC -0.18
- BIIB 0.57
- Stochastic Oscillator
- WDC 91.55
- BIIB 70.81
About WDC Western Digital Corporation
Western Digital is a leading, vertically integrated supplier of hard disk drives. The HDD market is a practical duopoly with, Western Digital and Seagate being the two largest players. Western Digital designs and manufacturers its HDDs, with much of the manufacturing and workforce located in Asia. The primary consumers of HDDs are data centers.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.